Clinical Trial Update: Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a single-dose anti-CD20 antibody in combination with bortezomib for relapsed or refractory autoimmune hemolytic anemia; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Evans Syndrome

Drugs mentioned

• Anti-CD20 antibody
• Bortezomib (bortezomib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia | Phase 2 | Status: COMPLETED